An IDH1 inhibitor for Grade 3 (n = 1) IDH-mt astrocytoma and FGFR inhibitors and pembrolizumab for diffuse midline glioma (n = 1) were recommended (Table S2). The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).